45.67
-1.42 (-3.02%)
| 前收盘价格 | 47.09 |
| 收盘价格 | 46.89 |
| 成交量 | 1,464,472 |
| 平均成交量 (3个月) | 2,218,020 |
| 市值 | 8,483,430,912 |
| 预期市盈率 (P/E Forward) | 2.50 |
| 价格/销量 (P/S) | 2.84 |
| 股市价格/股市净资产 (P/B) | 3.29 |
| 52周波幅 | |
| 利润日期 | 6 May 2025 - 12 May 2025 |
| 营业毛利率 | -37.29% |
| 营业利益率 (TTM) | -4.92% |
| 稀释每股收益 (EPS TTM) | -5.59 |
| 季度收入增长率 (YOY) | 10.30% |
| 总债务/股东权益 (D/E MRQ) | 115.55% |
| 流动比率 (MRQ) | 2.15 |
| 营业现金流 (OCF TTM) | 210.54 M |
| 杠杆自由现金流 (LFCF TTM) | 61.42 M |
| 资产报酬率 (ROA TTM) | -1.87% |
| 股东权益报酬率 (ROE TTM) | -37.09% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Exact Sciences Corporation | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.13 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.07% |
| 机构持股比例 | 100.62% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 73.00 (Scotiabank, 59.84%) | 购买 |
| 中 | 65.00 (42.33%) | |
| 低 | 52.00 (RBC Capital, 13.86%) | 保留 |
| 平均值 | 65.00 (42.33%) | |
| 总计 | 5 购买, 1 保留 | |
| 平均价格@调整类型 | 50.06 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 13 Mar 2025 | 52.00 (13.86%) | 保留 | 43.04 |
| Piper Sandler | 26 Feb 2025 | 70.00 (53.27%) | 购买 | 48.50 |
| Scotiabank | 24 Feb 2025 | 73.00 (59.84%) | 购买 | 51.28 |
| B of A Securities | 20 Feb 2025 | 65.00 (42.33%) | 购买 | 49.51 |
| Barclays | 20 Feb 2025 | 65.00 (42.33%) | 购买 | 49.51 |
| 23 Jan 2025 | 70.00 (53.27%) | 购买 | 55.13 | |
| Benchmark | 13 Jan 2025 | 65.00 (42.33%) | 购买 | 58.51 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合